Sanofi Reaches New 52-Week High (SNY)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- Sanofi (NYSE: SNY) hit a new 52-week high Friday as it is currently trading at $42.39, above its previous 52-week high of $42.31 with 99,879 shares traded as of 9:40 a.m. ET. Average volume has been 2.8 million shares over the past 30 days.

Sanofi has a market cap of $108.34 billion and is part of the health care sector and drugs industry. Shares are up 12.2% year to date as of the close of trading on Thursday.

Sanofi, together with its subsidiaries, researches, develops, manufactures, and markets healthcare products worldwide. The company has a P/E ratio of 22, above the average drugs industry P/E ratio of 14.7 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, expanding profit margins, increase in stock price during the past year, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Sanofi Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

Biotech Mailbag: Buy Dip in T2 Biosystems?

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids

Sanofi Has Good Potential Upside

European Pharma Companies Slip on MS Pricing Probe